Eledon Pharmaceuticals (ELDN) News Today $3.10 -0.21 (-6.34%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$3.10 0.00 (0.00%) As of 05/5/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Increase in Short InterestEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,750,000 shares, a growth of 19.9% from the March 31st total of 1,460,000 shares. Approximately 3.3% of the company's stock are short sold. Based on an average daily volume of 233,300 shares, the days-to-cover ratio is currently 7.5 days.May 5 at 7:03 PM | marketbeat.comAllostery Investments LP Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Allostery Investments LP purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the coMay 4 at 7:45 AM | marketbeat.com683 Capital Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)683 Capital Management LLC bought a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 154,960 shares of the company's stock, valued at apprMay 4 at 7:15 AM | marketbeat.com235,750 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC acquired a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 235,750 shares of the company's stock, valued at approximMay 4 at 7:11 AM | marketbeat.comEledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance SheetMay 3 at 9:04 AM | seekingalpha.comRA Capital Management L.P. Acquires New Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)RA Capital Management L.P. bought a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,566,338 shares of the company's stock, valueMay 3 at 7:49 AM | marketbeat.comEledon Pharmaceuticals (ELDN) to Release Earnings on ThursdayEledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-eledon-pharmaceuticals-inc-stock/)May 3 at 3:50 AM | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stakeMay 2, 2025 | finance.yahoo.comBoothbay Fund Management LLC Buys New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Boothbay Fund Management LLC purchased a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 341,923 shares of the company's stock, valuedMay 1, 2025 | marketbeat.comNantahala Capital Management LLC Raises Stock Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Nantahala Capital Management LLC lifted its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 91.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,147,946 shares of the company's stoApril 30, 2025 | marketbeat.comFirst Light Asset Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)First Light Asset Management LLC bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,328,768 shares of the company's stock, vaApril 30, 2025 | marketbeat.comGeode Capital Management LLC Buys 285,043 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Geode Capital Management LLC lifted its stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 75.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 663,101 shares of the company's stock after purchasing anApril 30, 2025 | marketbeat.comBlue Owl Capital Holdings LP Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Blue Owl Capital Holdings LP acquired a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,959,912 shares of the company's stock, valued at approximately $8,075,000.April 26, 2025 | marketbeat.comEAM Investors LLC Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)EAM Investors LLC purchased a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 109,555 shares of the company's stock, valued atApril 20, 2025 | marketbeat.comIs Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5?March 27, 2025 | uk.finance.yahoo.comCantor Fitzgerald Weighs in on ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Eledon Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the compaMarch 27, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now anticipates that the compaMarch 27, 2025 | marketbeat.comEquities Analysts Set Expectations for ELDN Q1 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.28) perMarch 26, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), Eledon Pharmaceuticals (ELDN)March 24, 2025 | markets.businessinsider.comGuggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)March 24, 2025 | markets.businessinsider.comWe're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash WiselyMarch 22, 2025 | finance.yahoo.comEledon Pharmaceuticals Reports 2024 Financial Results and Clinical AdvancesMarch 22, 2025 | tipranks.comEledon Pharmaceuticals (NASDAQ:ELDN) Posts Earnings Results, Misses Estimates By $0.30 EPSEledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.30).March 21, 2025 | marketbeat.comEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial ResultsMarch 20, 2025 | globenewswire.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 3.4% - Here's WhyEledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.4% - Should You Sell?March 5, 2025 | marketbeat.comEledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comLeerink Partnrs Has Pessimistic View of ELDN Q4 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.32) per shFebruary 10, 2025 | marketbeat.comEledon Pharmaceuticals' Investigational Therapy Tegoprubart Successfully Used in Landmark Kidney Xenotransplant at Mass General Transplant CenterFebruary 9, 2025 | nasdaq.comEledon's tegoprubart used in second pig-to-human kidney transplantFebruary 7, 2025 | msn.comEledon announces tegoprubart use in transplant of pig kidney into humanFebruary 7, 2025 | markets.businessinsider.comEledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a HumanFebruary 7, 2025 | globenewswire.comFY2029 Earnings Estimate for ELDN Issued By Leerink PartnrsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the companyFebruary 7, 2025 | marketbeat.comEledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comEledon Pharmaceuticals initiated with a Buy at GuggenheimJanuary 28, 2025 | markets.businessinsider.comEledon initiated with a Buy at Guggenheim on tegoprubart opportunityJanuary 28, 2025 | markets.businessinsider.comEledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessJanuary 28, 2025 | seekingalpha.comEledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at GuggenheimGuggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $9.00 target price for the company.January 28, 2025 | marketbeat.comInspire Investing LLC Invests $802,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Inspire Investing LLC acquired a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 194,688 shares of the company's stock, valued at approximately $802,000.January 25, 2025 | marketbeat.comBrokers Set Expectations for ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Eledon Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnJanuary 22, 2025 | marketbeat.comEledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top AnalystJanuary 16, 2025 | markets.businessinsider.comEledon Pharmaceuticals highlights recent business milestones, 2025 outlookJanuary 13, 2025 | msn.comEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 OutlookJanuary 13, 2025 | globenewswire.comEledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 3.9% - Time to Sell?Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.9% - Time to Sell?January 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest UpdateEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 686,700 shares, a drop of 6.1% from the November 15th total of 731,500 shares. Based on an average trading volume of 432,200 shares, the days-to-cover ratio is currently 1.6 days.December 16, 2024 | marketbeat.comQ4 EPS Forecast for Eledon Pharmaceuticals Cut by AnalystEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now expects that theNovember 22, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Eledon Pharmaceuticals in a research note on Wednesday.November 20, 2024 | marketbeat.comResearch Analysts Set Expectations for ELDN FY2024 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings per share estimates for Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the compaNovember 18, 2024 | marketbeat.comEledon Pharmaceuticals: Strong Financials and Promising Clinical Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for ELDN Issued By Lifesci CapitalEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Lifesci Capital lifted their FY2024 EPS estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per sNovember 15, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutionsNovember 14, 2024 | finance.yahoo.com Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELDN Media Mentions By Week ELDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼1.270.72▲Average Medical News Sentiment ELDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼131▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DAWN News Today OCS News Today CVAC News Today ABCL News Today RCKT News Today ZYME News Today QURE News Today XNCR News Today LENZ News Today PAHC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELDN Stock Free ELDN Stock Alerts